Leadership Team

Chris Simon was appointed CEO May 16, 2016. Previously, he served as a Senior Partner of McKinsey & Company where he led the Global Medical Products Practice. He brings more than 20 years of experience helping businesses transform and grow.

Mr. Simon was the lead partner for the strategy review with Haemonetics that launched in October 2015, where he gained invaluable insights into the company’s business and markets. Together with management and the board of directors, he co-architected the strategic plan that the company is now implementing.

He was with McKinsey since 1993. Before that he served in commercial and operating roles at Baxter Healthcare Corporation, and as a U.S. Army Infantry Officer in Korea and with the 1st Ranger Battalion.

Mr. Simon earned a Bachelor of Science in Economics from The Wharton School at the University of Pennsylvania and an MBA from Harvard Business School.

Michelle Basil joined Haemonetics in March 2017 as Executive Vice President, General Counsel. She is responsible for Haemonetics' Legal, Compliance and Corporate Audits and Controls groups.

Prior to joining Haemonetics, Ms. Basil was a Partner and Chair of the Life Sciences Practice Group at the Boston-based law firm Nutter, McClennen & Fish where she was legal counsel to public and private companies and their investors, principally in the life sciences and medical technology industries. At Nutter, Ms. Basil’s practice focused on corporate and securities law, including mergers and acquisitions, strategic collaborations, capital markets transactions, corporate governance and other matters affecting publicly traded companies and their officers and directors.

Ms. Basil is admitted to the bar in Massachusetts and holds both a Bachelor of Arts and a Juris Doctor from the University of California at Berkeley.

Said Bolorforosh, Ph.D. joined Haemonetics in 2018 as EVP, Chief Technology Officer. He leads the company’s innovation agenda and oversees research, development and medical and clinical affairs. He is responsible for developing technical capabilities and optimizing product and technology investments to drive accelerated growth.

Dr. Bolorforosh has more than 20 years’ experience in health care and medical devices. Most recently he was President, Ultrasound, at Siemens Healthcare, where he delivered positive growth and market share gains by rebuilding the product portfolio, improving sales and distribution capabilities and optimizing go-to-market strategies globally. He previously served as Vice President and General Manager of Intensive Insulin Delivery, Vice President of R&D and Chief Technology Officer for Medtronic’s Diabetes division, leading P&L as well as technology and product development. From 2004 to 2014, Dr. Bolorforosh held positions of increasing responsibility at General Electric’s Ultrasound division, including Global P&L Management, General Manager, Growth and Strategy; and Chief Technology Officer.

Dr. Bolorforosh holds a Bachelor of Science in Electronic and Electrical Engineering from Cardiff University, University of Wales and a doctorate in Electrical Engineering from University of London, King’s College London. He holds numerous patents and publications.

Bill Burke joined Haemonetics as Chief Financial Officer in August 2016 and is responsible for the global finance organization including investor relations. Previously, Mr. Burke was Chief Integration Officer and Vice President, Integration for the Medtronic/Covidien merger. Prior to this role, Mr. Burke worked at Covidien for more than nine years in various finance leadership roles including Chief Financial Officer for Europe, Vice President of Corporate Strategy and Portfolio Management and Vice President of FP&A.

Prior to Covidien, he held a number of roles within FP&A and Corporate Audit at Tyco Healthcare Group. Mr. Burke holds a Bachelor of Science in Business Administration from Bryant College with a focus in Accounting and is a Certified Public Accountant (CPA).

Josep Llorens joined Haemonetics as SVP, Global Manufacturing and Supply Chain in August 2018, and is responsible for expanding manufacturing capacity, upscaling strategic sourcing, driving greater throughput and improving product quality. Mr. Llorens brings over 20 years of experience in transforming supply chain, logistics and manufacturing operations to increase quality, improve customer satisfaction and reduce costs.

Previously, Mr. Llorens was Senior Vice President, Industrial Strategy and Advanced Manufacturing Engineering Leader for Philips Healthcare Diagnostic Imaging. Before that position, he held various Operations and Supply Chain roles within the Philips health care business, delivering supply chain and operations optimization in Diagnostics and Treatment, Patient Monitoring and Cardiac Care businesses and leading global teams focused on continuous improvement.

Mr. Llorens holds a bachelor's degree in Business Administration from University of Barcelona and a master's degree in Telecommunications Engineering from the Polytechnic University of Catalonia in Barcelona. He also received an Executive Certificate in Technology, Operations and Value Chain Management from the MIT Sloan School of Management.

Chad Nikel joined Haemonetics in 2009 as Site Director for the company’s Illinois facility, where he managed TEG operations, research and development, and marketing. In April 2011, he was promoted to Vice President, Global TEG, where he chartered a team in the global launch of the TEG product line and led an initiative to acquire a next generation technology for hemostasis monitoring. Mr. Nikel was promoted to Vice President, North America Blood Bank in September 2013, where he led commercial activities for the company’s Blood Center business and assumed global responsibility for the Whole Blood business in 2015. Mr. Nikel was promoted to Vice President, Global Blood Center, in 2017 and to his current role as President, Global Blood Center, in 2018.

Prior to joining Haemonetics, Mr. Nikel was Director, Strategy and Business Development at IPM Life Sciences. He previously held roles in research and development, operations and project management. Mr. Nikel began his career in the United States Air Force, where he served for five years and earned the rank of Captain.

Mr. Nikel holds a Bachelor of Science in both Civil Engineering and Environmental Engineering from the United States Air Force Academy and an MBA from St. Mary’s University.

Kevin O’Kelly-Lynch joined Haemonetics in December 2016 as Senior Vice President, Global Business Services. He has an extensive and seasoned background in global business and shared services spanning customer service and tech support, finance, procurement, IT, fleet and sales operations. He brings to Haemonetics the knowledge and experience to help the company successfully transform the way it creates enabling platforms to deliver critical services across multiple functions.

Mr. O’Kelly-Lynch most recently served as Vice President, Medtronic Business Services, where he led the Global Business Services Integration activity post the acquisition of Covidien, and managed a service delivery team of over 600 deployed in the United States, Europe and India. Prior to Medtronic, he was Vice President, Assistant Treasurer at Covidien plc, where he was responsible for global treasury operations. He has also held the position of International Treasurer & Managing Director at Tyco International, and Transfer Pricing Manager and Management Accountant at Diageo plc. He began his career at Fujitsu.

Mr. O’Kelly-Lynch received a Bachelor of Science in Management from Trinity College, Dublin and is a Chartered Global Management Accountant (CGMA).

Dr. Purdy has more than 20 years of experience in medical devices and diagnostics spanning all regions of the world, along with extensive experience in new product submissions, particularly in China, Europe, Japan and the U.S.

Most recently, he was Vice President, Clinical Regulatory and Quality Compliance at Thermo Fisher Scientific since 2012. He was responsible for the oversight and coordination of worldwide regulatory and quality compliance, overseeing a team of 2,500 employees at more than 100 global sites. He also held numerous clinical, regulatory and quality roles of increasing scope at Boston Scientific between 2000 and 2012, playing a critical role in ensuring regulatory and quality excellence for innovation-based products. He began his career working in clinical research at Smiths Medical.

Dr. Purdy holds a doctorate in Human Physiology (Haemodynamics) from the University of Southampton and a Bachelor of Science in Applied & Human Biology from Aston University (both in the UK). He also holds an Advanced Certificate in Management, Innovation and Technology from MIT’s Sloan School of Management.

Jacqueline Scanlan joined Haemonetics in March 2017 as Senior Vice President, Human Resources. She is responsible for the global Human Resources and Communications functions, with a focus on driving talent management.

Previously, Ms. Scanlan was Corporate Vice President, Human Resources, North America at Novo Nordisk. In this role, she led all aspects of the organization and people strategy for North America, and served as a key member of the Executive Team. Her responsibilities included organization development as well as change and talent management. Prior to Novo Nordisk, she held various HR leadership roles at Campbell Soup Company, including International HR, Global Talent Management and Organizational Effectiveness, and HR Business Partner. Earlier in her career, Ms. Scanlan held HR and consulting roles at Bristol-Myers Squibb, DuPont Pharmaceuticals Company and Accenture.

Ms. Scanlan received a Bachelor of Arts in Political Science from St. Joseph’s University and a Master of Science in Organizational Dynamics from the University of Pennsylvania.

Francis “Frank” Tan joined Haemonetics in June 2017 as Senior Vice President, Corporate Development and Planning. He is responsible for all of Haemonetics’ business development activities, including partnerships, collaborations, and mergers and acquisitions.

Previously, Mr. Tan was Vice President, Corporate Development at Thermo Fisher Scientific. While there, he developed and executed strategic growth initiatives across the company’s multiple businesses, representing roughly $18 billion in total revenues. He also led the execution of over a dozen merger and acquisition transactions valued at more than $30 billion. Prior to Thermo Fisher, Mr. Tan was Director, Business Development at EMD Millipore and held leadership roles in the company’s integration office during Millipore’s acquisition by Merck KGaA. He has an extensive background across all types of external licensing and partnership relationships as well as corporate strategy, product management, private equity, and financial analysis.

Mr. Tan holds a Bachelor of Arts from Amherst College and an MBA in Finance and Strategy from the Yale School of Management.

David J. Wilson joined Haemonetics in September 2017 as President, Global Plasma. He is a proven business leader with more than 20 years of experience in senior leadership roles at medical technology companies. He is responsible for expanding and strengthening the company’s market position in the plasma industry.

Mr. Wilson was most recently President, Cordis (a Cardinal Health company), which he led from March 2015 through August 2017. Cordis is a nearly $1 billion business focused on cardiovascular devices that Mr. Wilson brought back to profitable sales growth during his tenure as President. Prior to Cordis, Mr. Wilson held positions of increasing responsibility at Johnson & Johnson driving sales, marketing, research and development, operations and business development. He also worked previously in plasma-based sciences both at Ethicon Biosurgery and at Cohesion Corporation.

Mr. Wilson received a Bachelor of Mechanical Engineering from Auburn University, a Master of Science in Biomedical Engineering from the University of Alabama at Birmingham, and an MBA from Columbia University.